Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AB-101 is a novel, oral PD-L1 inhibitor, designed to allow for controlled checkpoint blockade, reawakens and boost the immune system of patients with chronic hepatitis B virus (cHBV).
Lead Product(s): AB-101
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
AB-101 is a novel, oral PD-L1 inhibitor designed to allow for controlled checkpoint blockade, reawakens and boost the immune system of patients with chronic hepatitis B virus (cHBV).
Lead Product(s): AB-101
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
AB-161 is an oral small molecule RNA destabilizer, designed to target the host proteins PAPD5/7, which are involved in regulating the stability of HBV RNA transcripts, thus reducing HBsAg levels and inhibiting viral replication in patients with hepatitis B virus.
Lead Product(s): AB-161
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-161
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
AB-343 inhibits the SARS-CoV-2 main protease (Mpro), a validated target for the treatment of COVID-19. In preclinical stage it has shown pan-coronavirus antiviral activity, and robust activity against SARS-CoV-2 Mpro resistant strains.
Lead Product(s): AB-343
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-343
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens including hepatitis B surface antigen which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
AB-729 is a RNA interference therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen which is thought to be key prerequisite to enable reawakening of a patient’s immune system to respond to virus.
Lead Product(s): AB-729,VTP-300
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
AB-101 is an oral, small molecule PD-L1 inhibitor candidate. Pre-clinical data showing that the combination of an HBV-targeting RNAi and AB-101 in mice infected with HBV, results in increased production of HBV-specific T-cells compared to administering an RNAi or AB-101 alone.
Lead Product(s): AB-101
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
AB-729 is a subcutaneously-delivered RNAi therapeutic specifically designed to reduce all HBV viral antigens, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to virus.
Lead Product(s): AB-729,Vebicorvir,Entecavir
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Assembly Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,Peginterferon Alfa 2A
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022